Axis Securities has set a goal worth of Rs 2,500 on Lupin, exhibiting an upside potential of round 23% from present market costs.
“New launches within the U.S. market, reminiscent of Darunavir and Spiriva, have gained market shares of as much as 30% and 25%, respectively. The latest approval for gMegabran has the potential to contribute $50 Mn in annual incremental gross sales. Moreover, approvals for Tolvaptan (market dimension $287 Mn) and Xyway (market dimension $958 Mn with 180-day exclusivity) may drive progress within the second half. The corporate has a sturdy product pipeline, which incorporates Cynocobalamin, Diazepam Gel, Varenicline, Bromfenac, Glucagen, and Risperidone, amongst others,” it stated.
